Schonfeld Strategic Advisors LLC Decreases Stake in Ascendis Pharma A/S (NASDAQ:ASND)

Schonfeld Strategic Advisors LLC lowered its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 39.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 138,593 shares of the biotechnology company's stock after selling 89,932 shares during the period. Schonfeld Strategic Advisors LLC owned approximately 0.23% of Ascendis Pharma A/S worth $19,080,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of ASND. T. Rowe Price Investment Management Inc. raised its holdings in shares of Ascendis Pharma A/S by 54.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company's stock worth $375,226,000 after buying an additional 960,504 shares during the last quarter. Capital International Investors increased its position in shares of Ascendis Pharma A/S by 35.7% in the 4th quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock valued at $394,183,000 after acquiring an additional 753,859 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Ascendis Pharma A/S by 7.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,283,207 shares of the biotechnology company's stock worth $314,330,000 after acquiring an additional 162,079 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in Ascendis Pharma A/S by 2.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company's stock worth $702,538,000 after acquiring an additional 114,167 shares during the period. Finally, FIL Ltd grew its stake in Ascendis Pharma A/S by 13.9% during the 4th quarter. FIL Ltd now owns 729,275 shares of the biotechnology company's stock valued at $100,399,000 after purchasing an additional 89,016 shares during the last quarter.

Ascendis Pharma A/S Trading Up 2.7 %

ASND traded up $4.59 during trading on Friday, hitting $172.06. The company's stock had a trading volume of 1,175,394 shares, compared to its average volume of 494,883. The firm has a market capitalization of $10.49 billion, a price-to-earnings ratio of -24.23 and a beta of 0.41. The business's fifty day simple moving average is $155.31 and its 200 day simple moving average is $140.33. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The company had revenue of $123.97 million for the quarter, compared to the consensus estimate of $98.56 million. As a group, equities research analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ASND shares. JPMorgan Chase & Co. raised their price objective on Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a research note on Friday. Evercore ISI raised their price target on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a research report on Friday. Wedbush upped their price objective on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a report on Friday. Morgan Stanley set a $180.00 target price on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th. Finally, The Goldman Sachs Group boosted their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Two research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $211.40.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.